The Growth Portfolio — How BMS Is Replacing $38B in Revenue

This module is the working knowledge of BMS's revenue future. Candidates should leave knowing the major growth-portfolio drugs by name, what disease each one treats, what makes each strategically important, and which acquisitions brought them in. This is the operational substrate behind the patent-cliff narrative from Module 02.